TIEFENBACHER GROUP becomes member of the Pharmaceutical Supply Chain Initiative (PSCI)
May 24, 2022
We at TIEFENBACHER GROUP are committed to promote sustainable and responsible business along the whole pharmaceutical supply chain. That’s why we are excited to become a member of PSCI – a…
TIEFENBACHER GROUP OPENS NEW SITE FOR HIGHLY POTENT DRUGS IN INDIA
May 5, 2022
TIEFENBACHER GROUP is excited to announce the ceremonious opening of our new highly potent drug laboratory in Hyderabad, India. The completion of the new building is the first step for…
WORLD HEALTH DAY @ TIEFENBACHER GROUP
April 7, 2022
Today we celebrate World Health Day. In times of a global pandemic and a cruel war in Europe, it is more important than ever that we all work together to create a healthier tomorrow. Since…
TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!
March 29, 2022
One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP…
NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE EPILEPSY MEDICINE LACOSAMIDE IN AUSTRALIA
March 22, 2022
We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their…
TIEFENBACHER GROUP STANDS WITH UKRAINE
March 8, 2022
To us at TIEFENBACHER GROUP, it is unbearable to witness what is happening in Ukraine. We condemn the Russian state´s invasion as a brutal act of war against a neighbouring sovereign…
MEET TIEFENBACHER GROUP DURING DCAT WEEK IN NEW YORK CITY FROM 21-24th MARCH!
February 9, 2022
Reach out to TIEFENBACHER GROUP at DCAT in New York City from 21-24th March and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before!…
TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!
January 4, 2022
We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three…
Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities
December 15, 2021
Did you know that TIEFENBACHER GROUP heavily invests in its own manufacturing facilities to secure an efficient and reliable supply of our high-quality pharmaceuticals for patients around the world?…
Three successful days for TIEFENBACHER GROUP at CPhI 2021 – thanks for visiting us in Milano!
November 17, 2021
With over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma event CPhI has just come to an end. It was three very successful days for TIEFENBACHER GROUP…
At TIEFENBACHER GROUP giving back to society is important to us: New school building in India
October 25, 2021
As a value-driven healthcare company, dedicated to improve the life of patients worldwide, we believe that it´s our responsibility to care about the environment and society –…
Reach out to TIEFENBACHER GROUP at CPhI in Milan from 9-11th Nov and discover our latest ideas to make pharmaceuticals more affordable, more available and better than before!
October 6, 2021
“Nothing can replace meeting each other in person!” says Oliver Schrader, Managing Director of Tiefenbacher Group. After nearly two years of mainly digital work, we are very excited to be back on the…
New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the antihistamine Bilastine
September 20, 2021
We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why we are excited…
New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP
May 26, 2021
Swedish Life science company OnDosis and German B2B pharmaceutical company TIEFENBACHER GROUP initiate four new innovative development projects targeting ADHD, rare diseases, and transplantation…
Spreading of Post COVID-19 Disease „Black Fungus“ in India – TIEFENBACHER GROUP supports with Posaconazole Tablets
May 19, 2021
Black Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised…
TIEFENBACHER GROUP announces global launch of TIEFENBACHER MEDICAL DEVICES
April 16, 2021
After more than five years in operation, TIEFENBACHER GROUP will transfer its medical device business into a new stand-alone company: TIEFENBACHER MEDICAL DEVICES. The launch follows TIEFENBACHER…
TIEFENBACHER PHARMACEUTICALS announces global launch of Teriflunomide making multiple sclerosis therapy more affordable and better available worldwide
February 23, 2021
TIEFENBACHER PHARMACEUTICALS, part of TIEFENBACHER GROUP, has successfully developed a global dossier for a generic version of Teriflunomide 7 mg and 14 mg film-coated tablets. Teriflunomide is an…
AET Pharma US Inc. Announces Successful approval of generic Posaconazole by the Food and Drug Administration (FDA)
February 8, 2021
On 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole 100 mg Delayed-Release Tablets. This is…
TIEFENBACHER PHARMACEUTICALS Announces Global Launch Of Rivaroxaban
January 26, 2021
TIEFENBACHER PHARMACEUTICALS, part of Tiefenbacher Group, is pleased to announce the availability of a registration dossier for the generic of Rivaroxaban 2.5 mg, 10 mg, 15 mg and 20 mg film-coated…
International Brand Relaunch of TIEFENBACHER GROUP
October 23, 2020
“We are very excited to launch our new AET website, representing the pharmaceutical FDF business of TIEFENBACHER GROUP. It is an important milestone within the international brand relaunch of our…
Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health
September 3, 2020
Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’…